In the news

As lifespans grow longer, targeted medical technology can help people live better, healthier lives—with fewer pills.

Dr. Janar Sathananthan, president, Interventional Cardiology, discusses the FRACTURE IDE trial, which met its primary endpoints for the SEISMIQ™ 4CE Coronary IVL Catheter in severely calcified coronary disease. The result underscores Boston Scientific’s broader intravascular lithotripsy commercialization strategy and differentiated cardiology solutions.

Karen Carlson’s incontinence kept her housebound for years despite various failed treatments. The Axonics™ Sacral Neuromodulation Therapy helped relieve her symptoms, restoring her active life.

This sponsored article explores how physicians are helping patients living with atrial fibrillation address two health issues at the same time: irregular heart rhythms and stroke risk.

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

The VAPEUR clinical trial compared Rezūm™ Water Vapor Therapy to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in sexually active men. Key findings from the study demonstrate that Rezūm Therapy provides superior BPH symptom relief versus combination therapy while preserving sexual function.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.

Kyra Williams shares her experience with endoscopic sleeve gastroplasty, a minimally invasive weight loss procedure that helped support her goals.

AI adoption is much bigger than a workplace tech initiative – it’s a change management challenge. That’s why, writes SVP of enterprise services and digital officer Jodi Euerle Eddy, “if your IT department aims to create an AI-enabled workforce, a close IT and HR partnership is essential.”

Read how the AGENT™ Drug Coated Balloon — now available in the U.S. — addresses a critical unmet need for in-stent restenosis (ISR) treatment, using tech that represents a “quantum leap” forward.

A recent survey highlights that women are seeking new ways to lose weight, as Boston Scientific launches Endura Weight Loss Solutions to increase awareness of minimally invasive weight loss procedures.

Ronald Morton, M.D., chief medical officer, Urology, Boston Scientific sheds light on two taboo topics affecting millions of men: erectile dysfunction (ED) and stress urinary incontinence (SUI).

At STAT’s AI-focused Breakthrough Summit West, Ken Stein, MD, senior vice president and global chief medical officer, shares how artificial intelligence is helping cardiologists make the leap from available insights to actionable ones.

At DeviceTalks Minnesota, Ken Stein, MD, senior vice president and global chief medical officer, outlines the steps Boston Scientific takes to evaluate a market, choose a development approach and establish the groundwork for adoption.

CEO Mike Mahoney shares lessons learned over his career that helped him shape Boston Scientific's winning culture and drive the company’s growth.

Lisa Considine, senior vice president of global talent, describes the professional development opportunities offered by Boston Scientific to early career talent that supports the company’s top ranking on Forbes’ list of America’s Best Employers for New Grads.

Dr. Michael R. Jaff, chief medical officer, Peripheral Interventions, discusses new data supporting the Eluvia™ Drug-Eluting Vascular Stent System presented at the Charing Cross Symposium. The article also explores how design elements of the device contribute to long-term outcomes in treating peripheral artery disease and future opportunities for innovation in drug-device combination therapies.

Ken Stein, MD, senior vice president and global chief medical officer, highlights how AI is being applied today to deliver more proactive, personalized and precise medical

Jodi Eddy, chief information and digital officer, explains the importance of ensuring IT teams at rapidly growing organizations are at the table when key initiatives are being discussed.

Boston Scientific has approximately doubled its Minnesota workforce in the last 15 years. It has become the largest employer in both Maple Grove and Arden Hills. And it’s not done expanding.

Jodi Eddy, chief information and digital officer, unpacks three aspects of corporate culture that are separating leaders from the pack in the global pursuit of generative AI adoption.

Dr. Brad Sutton, chief medical officer, Atrial Fibrillation Solutions, discusses two of the latest FARAPULSE™ Pulsed Field Ablation System innovations and how the acquisition of Cortex, Inc. will fit into the Boston Scientific Electrophysiology portfolio.